Exercise amplifies cardiovascular gains from GLP-1 therapy beyond weight loss
Nature Metabolism’s News & Views previews Sandsdal, Holt et al.’s findings that exercise alone, or in combination with the GLP-1 receptor agonist liraglutide, improves cardiovascular health markers and reduces carotid intima-media thickness. Liraglutide without exercise preserves weight loss but yields fewer cardiovascular benefits than exercise, highlighting benefits beyond weight loss for GLP-1 therapies in cardiovascular disease.